Jingtai Zhi and Jingzhu Zhao contributed equally and should be considered joint first authors.
The incidence of papillary thyroid microcarcinoma (PTMC) has been increasing globally in the past few decades. PTMC does not have a distinctive morphology that results in differences in biological behavior. The aim of this study was to classify PTMCs according to the morphological features and explore the relationship with clinicopathological characteristics. Additionally, we sought to evaluate whether different variants of PTMC can be an independent predictor for lymph mode metastasis when considering other risk factors.
Between December 2014 and December 2015, 1041 PTMC cases undergoing surgical resection at Tianjin Medical University Cancer Institute and Hospital were reviewed retrospectively. Statistical analysis was performed to investigate the independent factors for lymph node metastasis in PTMC.
Conventional variant PTMC (CPTMC), follicular variant PTMC (FPTMC), and encapsulated variant PTMC (EnPTMC) were major variants in PTMC, collectively accounting for 96.7% of the entire PTMC cohort.There were significant differences in clinicopathological characteristics among the three major variants. The frequency of aggressive parameters was significantly different among the three variants, including tumor size, minimal extrathyroidal extension (minimal ETE), and lymph node metastasis (all P < 0.05), being highest in CPTMC, lowest in EnPTMC, and intermediate in FPTMC. FPTMC (OR = 0.642, P = 0.003) and EnPTMC (OR = 0.540, P = 0.041) were independent protective factors for lymph node metastasis (LNM). In contrast, male gender (OR = 1.836, P = 0.000), age less than 45 years (OR = 1.457, P = 0.009), tumor size greater than 0.5 cm (OR = 1.453, P = 0.007), calcification (OR = 1.465, P = 0.016), minimal ETE (OR = 1.801, P = 0.001), and multifocality (OR = 1.721, P = 0.000) were independent risk factors for LNM.
The present study demonstrates the distinct biological behaviors of the three major PTMC variants and establishes an aggressive order of CPTMC ≫ FPTMC > EnPTMC. It is necessary to take into consideration variant-related risks and other independent predictors for the determination of lymphadenectomy in patients with PTMC.
Pedrazzini L, Baroli A, Marzoli L et al (2013) Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up. Minerva Endocrinol 38(3):269–279 PubMed
Jun HH, Kim SM, Hong SW et al (2014) Warthin-like variant of papillary thyroid carcinoma: single institution experience. ANZ J Surg. doi: 10.1111/ans.12725
Moreno A, Rodriguez JM, Sola J et al (1996) Encapsulated papillary neoplasm of the thyroid: retrospective clinicopathological study with long term follow up. Eur J Surg Acta Chir 162(3):177–180
Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133. doi: 10.1089/thy.2015.0020 CrossRefPubMedPubMedCentral
Liu LS, Liang J, Li JH et al (2016) The incidence and risk factors for central lymph node metastasis in cN0 papillary thyroid microcarcinoma: a meta-analysis. Eur Arch Oto-Rhino-Laryngol. doi: 10.1007/s00405-016-4302-0
Zhang L, Yang J, Sun Q et al (2016) Risk factors for lymph node metastasis in papillary thyroid microcarcinoma: older patients with fewer lymph node metastases. Eur J Surg Oncol 42(10):1478–1482. doi: 10.1016/j.ejso.2016.07.002
Thompson LD (2016) Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma: a name change to Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features would help prevent overtreatment. Mod Pathol 29(7):698–707. doi: 10.1038/modpathol.2016.65 CrossRefPubMed
- Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases
- Springer Japan
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II